Business alliance with Aduro


Our attorneys advised longtime client Novartis on a significant multiyear alliance with California-based Aduro Biotech that is intended to enhance efforts to combat cancer by harnessing the body’s immune system. The alliance will focus on developing next generation cancer immunotherapies targeting the Stimulator of Interferon Genes (STING) pathway. Under the terms of the agreement with Aduro, Novartis will make an upfront payment of $200 million to Aduro and will make an initial equity investment in the company for $25 million, with a commitment for another $25 million equity investment at a future date.


Email Disclaimer